Aberdeen Group plc Raises Holdings in McKesson Corporation $MCK

Aberdeen Group plc increased its stake in shares of McKesson Corporation (NYSE:MCK) by 61.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 113,077 shares of the company’s stock after acquiring an additional 43,106 shares during the quarter. Aberdeen Group plc owned approximately 0.09% of McKesson worth $86,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. J.W. Cole Advisors Inc. boosted its holdings in McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after purchasing an additional 1,329 shares during the last quarter. Private Wealth Partners LLC lifted its holdings in shares of McKesson by 5.6% during the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after buying an additional 1,682 shares during the period. AlphaQuest LLC boosted its stake in shares of McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after buying an additional 843 shares during the last quarter. CW Advisors LLC grew its holdings in shares of McKesson by 282.5% in the second quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after acquiring an additional 8,130 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in McKesson by 12.4% during the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after acquiring an additional 36,451 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Trading Up 1.9%

NYSE:MCK opened at $933.75 on Monday. The stock has a 50-day moving average price of $840.13 and a 200 day moving average price of $788.58. McKesson Corporation has a 12-month low of $585.22 and a 12-month high of $971.93. The stock has a market capitalization of $114.38 billion, a P/E ratio of 26.86, a P/E/G ratio of 1.50 and a beta of 0.40.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a $0.82 dividend. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s payout ratio is presently 9.43%.

Analysts Set New Price Targets

Several brokerages have issued reports on MCK. TD Cowen raised their target price on McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Wells Fargo & Company raised their price objective on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a report on Thursday, February 5th. Evercore reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of McKesson in a report on Thursday, November 6th. Barclays assumed coverage on shares of McKesson in a research report on Monday, December 8th. They issued an “overweight” rating and a $960.00 price target on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a research note on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, McKesson currently has an average rating of “Moderate Buy” and a consensus target price of $937.07.

Insider Activity

In related news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the sale, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by corporate insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.